Use of Dupilumab to Manage Antibody-Drug Conjugate–Induced Cutaneous Toxicities

This case series examines the effectiveness of dupilumab as a steroid-sparing therapy among patients with antibody-drug conjugate–related cutaneous toxicities.

Corresponding Author: Allison Gordon, MD, Dermatology Service, Memorial Sloan Kettering Cancer Center, 545 E 73rd St, New York, NY 10021 (gordona3@mskcc.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.